Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Medroxyprogesterone acetate (formerly NSC26386; NSC 26386; Medroxyprogesterone 17-acetate; MPA), the 17-ester form of Medroxyprogesterone, is a steroidal progestin and a synthetic variant of the human hormone progesterone. It is commonly used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis. Medroxyprogesterone acetate inhibits the enzyme 3-hydroxyste-roid dehydrogenase, involved in the reversible conversion between 5alpha-dihydroprogesterone and 3alpha, 5alpha-tetrahydroprogesterone.
ln Vitro |
In steroid-deprived HUVEC, medroxyprogesterone acetate (10 and 0.5 nM, 48 hours) suppresses eNOS expression [2]. Medroxyprogesterone acetate (10 and 0.5 nM, 16 hours) decreases the expression of endothelial adhesion molecules (VCAM-1 and ICAM-1 protein), which prevents leukocytes from adhering to human endothelial cells (steroid-deprived HUVEC) [2]. In steroid-deprived HUVEC, medroxyprogesterone acetate (10 and 0.5 nM, 2 hours) decreases NF-κB nuclear translocation [2].
|
||
---|---|---|---|
ln Vivo |
AUC0- 2535.9 ng·h/mL, t1/2 of 10.2 hours, and Cmax of 377.9 ng/mL were observed in rats given 5 mg/kg of medroxyprogesterone acetate by gavage [3]. Over the course of 14 days, rats given oral medroxyprogesterone acetate (0.05-0.2 mg/kg/day) showed an increase in allopregesterone levels in all tissues except the adrenal gland and a change in β-END levels in the hippocampus [4].
|
||
Cell Assay |
Immunofluorescence[2]
Cell Types: 100 ng/ml LPS treated endothelial cells Tested Concentrations: 10 and 0.5 nM Incubation Duration: 2h Experimental Results: Inhibited NF-κB nuclear translocation. |
||
Animal Protocol |
|
||
References |
Molecular Formula |
C24H34O4
|
|
---|---|---|
Molecular Weight |
386.52
|
|
CAS # |
71-58-9
|
|
Related CAS # |
Medroxyprogesterone acetate;71-58-9
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
O(C(C([H])([H])[H])=O)[C@]1(C(C([H])([H])[H])=O)C([H])([H])C([H])([H])[C@@]2([H])[C@]3([H])C([H])([H])[C@]([H])(C([H])([H])[H])C4=C([H])C(C([H])([H])C([H])([H])[C@]4(C([H])([H])[H])[C@@]3([H])C([H])([H])C([H])([H])[C@@]21C([H])([H])[H])=O
|
|
InChi Key |
PSGAAPLEWMOORI-PEINSRQWSA-N
|
|
InChi Code |
InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
|
|
Chemical Name |
(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (2.59 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (2.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (2.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5872 mL | 12.9359 mL | 25.8719 mL | |
5 mM | 0.5174 mL | 2.5872 mL | 5.1744 mL | |
10 mM | 0.2587 mL | 1.2936 mL | 2.5872 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.